Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
March 15, 2024International Journal of Drug Regulatory AffairsOpen Access

Nitrosamine Contamination in Pharmaceuticals: Regulatory Perspectives and Control Strategies of USFDA, EMA & HC

View Full Paper
Ask AI
Bookmark
Share

Authors

NPNidhi PardeshiVSVijay SataparaKPKajal Patel

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Pardeshi et al. (2024) studied this question.

synapsesocial.com/papers/68e73dcfb6db6435876b75d8https://doi.org/10.22270/ijdra.v12i1.624
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Innovations in the Detection of N-Nitrosamine Impurities in Pharmaceuticals: Analytical and Regulatory Challenges2025 · 9 citations
  2. 2A Review on Nitrosamines Impurities in Pharmaceuticals-From Contamination Sources to Analytical Determination2026
  3. 3Nitrosamine contamination of pharmaceuticals: Cases in Japan, formation mechanisms, detection methods, regulatory perspectives, and insights2024 · 12 citations
  4. 4Review on Nitrosamine: A Potential Genotoxic Impurity2025 · 1 citations
  5. 5The Nitrite-Amines Nexus in Nitrosamine Formation: Mechanisms, Mutagenic Implications, Regulations, and Root Causes in Medicines2025